The Regentime stem cell procedure efficacy in asthma treatment: A case report

Asthma is a chronic respiratory condition affecting millions worldwide. It is characterized by airway inflammation leading to airflow obstruction and bronchial hyperresponsiveness. Despite optimal pharmacological treatment, some people fail to achieve full control of their symptoms and suffer from recurrent debilitating asthma attacks.

We report the case of a 54-year-old female patient who originally presented for stem cell treatment of her ankle. She complained of chronic left ankle pain and swelling that worsened with weight-bearing activities. During her medical history taking, she described experiencing dyspnea and wheezing both during the daytime and on more than 1 night weekly.

She had an obstructive pattern on spirometry and her symptoms were consistent with the diagnosis of moderate persistent asthma. She was also previously diagnosed with osteoarthritis affecting her tibiotalar and talocalcaneal joints.

The patient received partially differentiated autologous stem cells in her affected joints. Another portion of stem cells was treated and administered to her via inhalation according to the Regentime protocol for lung regeneration.

Upon regular follow-up, the patient reported gradual improvement of her osteoarthritis symptoms, reaching full recovery of the ankle within 5 months following treatment. She also noted the progressive amelioration of her asthma manifestations until their disappearance during the first month after stem cell administration. Her clinical remission was maintained for at least 24 months with ongoing follow-up to date and progressive improvement on physical examination.

The successful outcome of this case marks the potential of the Regentime stem cell protocol for lung regeneration as a promising therapeutic approach for managing chronic respiratory conditions such as asthma.